US8987424B2ExpiredUtilityPatentIndex 47
CA6 antigen-specific cytotoxic conjugate and methods of using the same
Est. expiryJul 21, 2023(expired)· nominal 20-yr term from priority
C07K 2317/56C07K 16/3092A61K 39/39558A61K 2039/505A61K 47/6855C07K 14/4748A61K 47/6859C07K 16/3015C07K 2317/24A61K 31/537C07K 14/4727C07K 2317/567A61K 47/6877C07K 2317/565A61K 47/6809A61P 35/00C07K 2317/92C07K 16/464C07K 2317/73A61K 47/6869C07K 16/3069C07K 2317/14A61K 47/6851C07K 16/303A61K 47/48569A61K 47/48407A61K 47/48384A61K 47/68033A61K 47/6803
47
PatentIndex Score
0
Cited by
72
References
71
Claims
Abstract
Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A cytotoxic conjugate comprising a cell binding agent and a cytotoxic agent, wherein said cell binding agent comprises an antibody or fragment thereof which binds to CA6 glycotope, wherein said antibody or fragment thereof comprises at least one heavy chain variable region and at least one light chain variable region;
wherein said heavy chain variable region comprises CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of amino acids 31-35, 50-66, and 99-106 of SEQ ID NO:11, respectively; and
wherein said light chain variable region comprises CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of amino acids 24-33, 49-55, and 88-96 of SEQ ID NO:8, respectively.
2. The cytotoxic conjugate according to claim 1 , wherein said cell binding agent and said cytotoxic agent are covalently linked.
3. The cytotoxic conjugate according to claim 1 , wherein said cell binding agent and said cytotoxic agent are covalently linked through a PEG linking group.
4. The cytotoxic conjugate according to claim 1 , wherein said cell binding agent and said cytotoxic agent are covalently linked through a thiol or disulfide functionality of said cytotoxic agent.
5. The cytotoxic conjugate according to claim 1 , wherein said cell binding agent is a humanized antibody.
6. The cytotoxic conjugate according to claim 1 , wherein said fragment of an antibody is selected from the group consisting of a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a single-chain Fvs (scFv) fragment, a single-chain antibody, and a disulfide-linked Fvs (sdFv) fragment.
7. The cytotoxic conjugate according to claim 1 , wherein said cytotoxic agent is member selected from the group consisting of a maytansinoid compound, a taxoid compound, a CC-1065 compound, a dolastatin compound, a daunorubicin compound, and a doxorubicin compound.
8. The cytotoxic conjugate according, to claim 7 , wherein said cytotoxic agent is the maytansinoid compound DM1 of formula (I):
9. The cytotoxic conjugate according, to claim 7 , wherein said cytotoxic agent is the maytansinoid compound DM4 of formula (II):
10. The cytotoxic conjugate according, to claim 7 , wherein said cytotoxic agent is the maytansinoid compound of formula (III):
wherein:
Y′ represents (CR 7 R 8 ) l (CR 9 ═CR 10 ) p C≡C q A o (CR 5 R 6 ) m D u (CR 11 ═CR 12 ) r (C≡C) s B t (CR 3 R 4 )—CR 1 R 2 SZ,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
A, B, D are cycloalkyl or cycloalkenyl having 3-10 carbon atoms, simple or substituted aryl or heterocyclic aromatic or heterocyclic radical;
R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical;
l, m, n, o, p, q, r, s, t, and u are each independently 0 or an integer of from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s t, and u are not zero at any one time; and
Z is H, SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocyclic radical.
11. The cytotoxic conjugate according to claim 10 , wherein R 1 is methyl, R 2 is H and Z is H.
12. The cytotoxic conjugate according to claim 10 , wherein R 1 and R 2 are methyl and Z is H.
13. The cytotoxic conjugate according to claim 10 , wherein R 1 is methyl, R 2 is H, and Z is —SCH 3 .
14. The cytotoxic conjugate according to claim 10 , wherein R 1 and R 2 are methyl, and Z is —SCH 3 .
15. The cytotoxic conjugate according, to claim 10 , wherein said cytotoxic agent is a maytansinoid compound selected from the group consisting of formulas (IV-L), (IV-D), and (IV-D,L):
wherein:
Y represents (CR 7 R 8 ) l (CR 5 R 6 ) m (CR 3 R 4 ) n CR 1 R 2 SZ,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromatic or heterocyclic radical;
l, m and n are each independently an integer of from 1 to 5, and in addition n can be 0;
Z is H, SR or —COR wherein R is linear or branched alkyl or alkenyl having from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocyclic radical; and
May represents a maytansinoid which bears the side chain at C-3, C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl.
16. The cytotoxic conjugate according to claim 15 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 , and R 8 are each H, l and m are each 1, n is 0, and Z is H.
17. The cytotoxic conjugate according to claim 15 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , R 8 are each H, l and m are 1, n is 0, and Z is H.
18. The cytotoxic conjugate according to claim 15 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 , and R 8 are each H, l and m are each 1, n is 0, and Z is —SCH 3 .
19. The cytotoxic conjugate according to claim 15 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , and R 8 are each H, l and m are 1, n is 0, and Z is —SCH 3 .
20. The cytotoxic conjugate according to claim 15 , wherein the cytotoxic agent is represented by formula (IV-L).
21. The cytotoxic conjugate according, to claim 15 , wherein said cytotoxic agent is the maytansinoid compound formula (V):
wherein:
Y represents
(CR 7 R 8 ) l (CR 5 R 6 ) m CR 3 R 4 ) n CR 1 R 2 SZ,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 , are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromatic or heterocyclic radical; and
l, m and n are each independently an integer of from 1 to 5, and in addition n can be 0;
Z is H, SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocyclic radical.
22. The cytotoxic conjugate according to claim 21 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 , and R 8 are each H; l and m are each 1; n is 0; and Z is H.
23. The cytotoxic conjugate according to claim 21 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , R 8 are each H, l and m are 1; n is 0; and Z is H.
24. The cytotoxic conjugate according to claim 21 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 , and R 8 are each H, l and m are each 1, n is 0, and Z is —SCH 3 .
25. The cytotoxic conjugate according to claim 21 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , R 8 are each H, l and m are 1, n is 0, and Z is —SCH 3 .
26. The cytotoxic conjugate according to claim 7 , wherein said cytotoxic agent is a maytansinoid compound selected from the group consisting of formulas (VI-L), (VI-D), and (VI-D,L):
wherein:
Y 2 represents
(CR 7 CR 8 ) l (CR 5 R 6 ) m (CR 3 R 4 ) n CR 1 R 2 SZ 2 ,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 2 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 , are each independently H, CH 3 , C 2 H 5 , linear cyclic alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical
l, m and o are each independently an integer of from 1 to 5, and in addition n can be 0;
Z 2 is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocyclic radical; and
May is a maytansinoid.
27. The cytotoxic conjugate according, to claim 7 , wherein said cytotoxic agent is the maytansinoid compound of formula (VII):
or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocyclic radical
wherein:
Y 2 ′ represents
(CR 7 CR 8 ) l (CR 9 ═R 10 ) p (C≡C) q A o (CR 5 R 6 ) m D u (CR 11 ═CR 12 ) r (C≡C) s B t (CR 3 R 4 ) n CR 1 R 2 S—,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear branched or alkyl or alkenyl having from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
A, B, and D each independently is cycloalkyl or cycloalkenyl having 3 to 10 carbon atoms, simple or substituted aryl, or heterocyclic aromatic or heterocyclic radical;
R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical;
l, m, n, o, p, q, r, s, t and u are each independently 0 or an integer of from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s t and u are not zero at any one time; and
Z 2 is SR or —COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3-10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocyclic radical.
28. The cytotoxic conjugate according to claim 27 , wherein R1 is methyl and R2 is H.
29. The cytotoxic conjugate according to claim 7 , wherein said cytotoxic agent is the maytansinoid compound of formula (VIII):
wherein:
Y 1 ′ represents
(CR 7 R 8 ) l (CR 9 ═R 10 ) p (C≡C) q A o (CR 5 R 6 ) m D u (CR 11 ═CR 12 ) r (C≡C) s B t (CR 3 R 4 ) n CR 1 R 2 S—,
wherein:
A, B, and D, each independently is cycloalkyl or cycloalkenyl having 3-10 carbon atoms, simple or substituted aryl, or heterocyclic aromatic or heterocyclic radical;
R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical; and
l, m, n, o, p, q, r, s, t, and u are each independently 0 or an integer of from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s t, and u are not zero at any one time.
30. The cytotoxic conjugate according to claim 29 , wherein R 1 is methyl and R 2 is H.
31. The cytotoxic conjugate according to claim 29 , wherein R 1 and R 2 are methyl.
32. The cytotoxic conjugate according, to claim 7 , wherein said cytotoxic agent is a maytansinoid compound selected from the group consisting of formulas (IX-L), (IX-D), and (IX-D,L):
wherein:
Y 1 represents (CR 7 R 8 ) l (CR 5 R 6 ) m (CR 3 R 4 ) n CR 1 R 2 S—, wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical;
l, m and n are each independently an integer of from 1 to 5, and in addition n can be 0; and
May represents a maytansinol which bears the side chain at C-3, C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl.
33. The cytotoxic conjugate according to claim 32 , wherein R 1 is methyl and R 2 is H or R 1 and R 2 are methyl.
34. The cytotoxic conjugate according to claim 32 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 and R 8 are each H; l and m are each 1; n is 0.
35. The cytotoxic conjugate according to claim 32 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , R 8 are each H, l and m are 1, n is 0.
36. The cytotoxic conjugate according to claim 33 , wherein the maytansinoid is represented by formula (IX-L).
37. The cytotoxic conjugate according to claim 34 , wherein the maytansinoid is represented by formula (IX-L).
38. The cytotoxic conjugate according to claim 35 , wherein the maytansinoid is represented by formula (IX-L).
39. The cytotoxic conjugate according to claim 7 , wherein said cytotoxic agent is the maytansinoid compound of formula (X):
wherein:
Y 1 represents (CR 7 R 8 ) l (CR 5 R 6 ) m (CR 3 R 4 )nCR 1 R 2 S—,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical;
l, m and n are each independently an integer of from 1 to 5, and in addition n can be 0; and
May represents a maytansinol which bears the side chain at C-3, C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl.
40. The cytotoxic conjugate according, to claim 39 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 , and R 8 are each H, l and m are 1, and n is 0.
41. The cytotoxic conjugate according, to claim 39 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , and R 8 are each H, l and m are 1, and n is 0.
42. The cytotoxic conjugate according to claim 1 , wherein said cytotoxic agent is DM1 or DM4.
43. The cytotoxic conjugate according, to claim 7 , wherein said cytotoxic agent is the taxane formula (XI):
44. The cytotoxic conjugate according to claim 1 , wherein said cell binding agent and said cytotoxic agent are covalently linked via a N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) linker, wherein said cytotoxic agent is the maytansinoid compound DM4 of formula (II):
45. The cytotoxic conjugate according to claim 44 , wherein 1-10 DM4 molecules are linked to said cell binding agent.
46. A humanized antibody or fragment thereof which binds to CA6 glycotope, wherein said antibody or fragment thereof comprises at least one heavy chain variable region and at least one light chain variable region;
wherein said heavy chain variable region comprises CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of amino acids 31-35, 50-66, and 99-106 of SEQ ID NO:11, respectively; and
wherein said light chain variable region comprises CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of amino acids 24-33, 49-55, and 88-96 of SEQ ID NO:8, respectively.
47. A cytotoxic conjugate comprising a cell binding agent and a cytotoxic agent, wherein said cell binding agent comprises an antibody or fragment thereof which binds to CA6 glycotope, wherein said antibody or fragment thereof comprises at least one heavy chain variable region and at least one light chain variable region; wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO:10 or SEQ ID NO:11; and wherein said light chain variable region comprises the amino acid sequence SEQ ID NO:8.
48. The cytotoxic conjugate according to claim 47 , wherein said cell binding agent and said cytotoxic agent are covalently linked.
49. The cytotoxic conjugate according to claim 47 , wherein said cell binding agent and said cytotoxic agent are covalently linked through a PEG linking group.
50. The cytotoxic conjugate according to claim 47 , wherein said cell binding agent and said cytotoxic agent are covalently linked through a thiol or disulfide functionality of said cytotoxic agent.
51. The cytotoxic conjugate according to claim 47 , wherein said fragment of an antibody is selected from the group consisting of a Fab fragment, a Fab′ fragment, a F(ab′)2 fragment, a single-chain Fvs (scFv) fragment, a single-chain antibody, and a disulfide-linked Fvs (sdFv) fragment.
52. The cytotoxic conjugate according to claim 47 , wherein said cytotoxic agent is selected from the group consisting of a maytansinoid compound, a taxoid compound, a CC-1065 compound, a dolastatin compound, a daunorubicin compound, and a doxorubicin compound.
53. The cytotoxic conjugate according, to claim 52 , wherein said cytotoxic agent is the maytansinoid compound DM1 of formula (I):
54. The cytotoxic conjugate according, to claim 52 , wherein said cytotoxic agent is the maytansinoid compound DM4 of formula (II):
55. The cytotoxic conjugate according, to claim 52 , wherein said cytotoxic agent is the maytansinoid compound of formula (VIII):
wherein:
Y 1 ′ represents
(CR 7 R 8 ) l (CR 9 ═R 10 ) p (C≡C) q A o (CR 5 R 6 ) m D u (CR 11 ═CR 12 ) r (C≡C) s B t (CR 3 R 4 ) n CR 1 R 2 S—,
wherein:
A, B, and D, each independently is cycloalkyl or cycloalkenyl having 3-10 carbon atoms, simple or substituted aryl, or heterocyclic aromatic or heterocyclic radical;
R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical; and
l, m, n, o, p, q, r, s, t, and u are each independently 0 or an integer of from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s t, and u are not zero at any one time.
56. The cytotoxic conjugate according to claim 55 , wherein R 1 is methyl and R 2 is H.
57. The cytotoxic conjugate according, to claim 55 , wherein R 1 and R 2 are methyl.
58. The cytotoxic conjugate according, to claim 52 , wherein said cytotoxic agent is a maytansinoid compound selected from the group consisting of formulas (IX-L), (IX-D), and (IX-D,L):
wherein:
Y 1 represents (CR 7 R 8 ) l (CR 5 R 6 ) m (CR 3 R 4 ) n CR 1 R 2 S—, wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical;
l, m and n are each independently an integer of from 1 to 5, and in addition n can be 0; and
May represents a maytansinol which bears the side chain at C-3, C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl.
59. The cytotoxic conjugate according to claim 58 , wherein R 1 is methyl and R 2 is H or R 1 and R 2 are methyl.
60. The cytotoxic conjugate according to claim 58 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 and R 8 are each H; l and m are each 1; n is 0.
61. The cytotoxic conjugate according to claim 58 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , R 8 are each H, l and m are 1, n is 0.
62. The cytotoxic conjugate according to claim 59 , wherein the maytansinoid is represented by formula (IX-L).
63. The cytotoxic conjugate according to claim 60 , wherein the maytansinoid is represented by formula (IX-L).
64. The cytotoxic conjugate according to claim 61 , wherein the maytansinoid is represented by formula (IX-L).
65. The cytotoxic conjugate according to claim 52 , wherein said cytotoxic agent is a maytansinoid compound of formula (X):
wherein:
Y 1 represents (CR 7 R 8 ) l (CR 5 R 6 ) m (CR 3 R 4 )nCR 1 R 2 S—,
wherein:
R 1 and R 2 are each independently CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, heterocyclic aromatic or heterocyclic radical, and in addition R 2 can be H;
R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently H, CH 3 , C 2 H 5 , linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or heterocyclic radical;
l, m and n are each independently an integer of from 1 to 5, and in addition n can be 0; and
May represents a maytansinol which bears the side chain at C-3, C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl.
66. The cytotoxic conjugate according, to claim 65 , wherein R 1 is methyl, R 2 is H, R 5 , R 6 , R 7 , and R 8 are each H, l and m are 1, and n is 0.
67. The cytotoxic conjugate according, to claim 65 , wherein R 1 and R 2 are methyl, R 5 , R 6 , R 7 , and R 8 are each H, l and m are 1, and n is 0.
68. The cytotoxic conjugate according, to claim 47 , wherein said cytotoxic agent is DM1 or DM4.
69. The cytotoxic conjugate according, to claim 47 , wherein said cytotoxic agent is the taxane formula (XI):
70. The cytotoxic conjugate according, to claim 47 , wherein said cell binding agent and said cytotoxic agent are covalently linked via a N-succinimidyl 4-(2-pyridyldithio)butanoate (SPDB) linker, wherein said cytotoxic agent is the maytansinoid compound DM4 of formula (II):
71. The cytotoxic conjugate according to claim 70 , wherein 1-10 DM4 molecules are linked to said cell binding agent.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.